Core Viewpoint - Fujilai's stock has shown significant growth this year, with a year-to-date increase of 52.95%, indicating strong market performance and investor interest [1][2]. Company Overview - Fujilai Pharmaceutical Co., Ltd. is located in Changshu, Jiangsu Province, and was established on November 27, 2000. The company went public on March 29, 2022, and specializes in the research, production, and sales of active pharmaceutical ingredients and health product raw materials [1]. - The main revenue sources for Fujilai include: 66.02% from alpha-lipoic acid products, 14.86% from carnosine products, 11.88% from etoricoxib, 5.95% from phosphatidylcholine products, and 1.29% from other supplementary products [1]. Financial Performance - For the period from January to September 2025, Fujilai achieved an operating income of 323 million yuan, representing a year-on-year growth of 3.23%. The net profit attributable to shareholders was 73.40 million yuan, showing a substantial increase of 430.16% [2]. - Since its A-share listing, Fujilai has distributed a total of 153 million yuan in dividends, with 116 million yuan distributed over the past three years [3]. Shareholder Information - As of October 20, 2025, Fujilai had 11,000 shareholders, a decrease of 0.47% from the previous period. The average number of circulating shares per shareholder increased by 0.47% to 8,083 shares [2]. - Among the top ten circulating shareholders, Galaxy Kangle Stock A (519673) is the ninth largest, holding 178,100 shares as a new shareholder [3].

Core Viewpoint - Fujilai's stock price has experienced fluctuations, with a year-to-date increase of 49.68% and a recent decline of 2.00% on October 24, 2023, indicating volatility in market performance [1][2]. Financial Performance - For the period from January to September 2025, Fujilai reported a revenue of 323 million yuan, reflecting a year-on-year growth of 3.23%. The net profit attributable to shareholders reached 73.4 million yuan, showing a significant increase of 430.16% [3]. - Since its A-share listing, Fujilai has distributed a total of 153 million yuan in dividends, with 116 million yuan distributed over the past three years [4]. Stock Market Activity - As of October 20, 2023, Fujilai had 11,000 shareholders, a decrease of 0.47% from the previous period. The average number of circulating shares per shareholder increased by 0.47% to 8,083 shares [3]. - The stock has been active on the market, appearing on the "Dragon and Tiger List" twice this year, with the most recent instance on July 8, 2023, where it recorded a net buy of -7.94 million yuan [2]. Shareholder Composition - As of September 30, 2025, Fujilai's top ten circulating shareholders included a new entrant, Galaxy Kangle Stock A, holding 178,100 shares, representing a notable addition to the shareholder base [4]. Business Overview - Fujilai, established on November 27, 2000, and listed on March 29, 2022, specializes in the research, production, and sales of active pharmaceutical ingredients and health product raw materials. Its main revenue sources include products such as alpha-lipoic acid (66.02%), carnosine (14.86%), and others [2].

Group 1 - Fujilay's stock price decreased by 1.57% on October 13, with a trading volume of 42.4662 million yuan. The margin trading data shows a financing buy amount of 3.7234 million yuan and a financing repayment of 3.8697 million yuan, resulting in a net financing buy of -0.1463 million yuan. As of October 13, the total margin trading balance is 67.8946 million yuan [1] - The financing balance of Fujilay is 67.8946 million yuan, accounting for 2.22% of the circulating market value, which is above the 50th percentile level over the past year, indicating a relatively high position [1] - On the short selling side, Fujilay had no shares repaid or sold on October 13, with a short selling balance of 0.00 shares, which is above the 80th percentile level over the past year, indicating a high position [1] Group 2 - As of September 30, Fujilay had 11,100 shareholders, an increase of 0.94% from the previous period, with an average of 8,049 circulating shares per person, which is an increase of 160.64% [2] - For the first half of 2025, Fujilay achieved an operating income of 224 million yuan, a year-on-year increase of 3.36%, and a net profit attributable to the parent company of 43.0766 million yuan, a significant year-on-year increase of 12,430.96% [2] - Fujilay has distributed a total of 153 million yuan in dividends since its A-share listing, with 116 million yuan distributed over the past three years [3]

Core Viewpoint - Fujilai Pharmaceutical Co., Ltd. plans to repurchase shares through centralized bidding, with a total amount between 20 million and 40 million yuan, and a maximum repurchase price of 40.00 yuan per share, funded by its own resources, within a 12-month period [1] Group 1: Share Repurchase Details - The current share price of Fujilai is 33.32 yuan, reflecting a year-to-date increase of 41.48%. The proposed maximum repurchase price represents a 20.05% premium over the current price [1] - This is the second share repurchase announcement for the year, with the first occurring on July 7, 2025, also with a repurchase range of 20 million to 40 million yuan and a maximum price of 40.00 yuan per share [1] - Since the last repurchase announcement, the company has repurchased 1.11 million shares, totaling approximately 39.75 million yuan, with a stock price increase of 1.80% during that period [1] Group 2: Company Overview - Fujilai, established on November 27, 2000, and listed on March 29, 2022, is located in Changshu, Jiangsu Province, focusing on the research, production, and sales of APIs and health product raw materials [2] - The main revenue sources include: 66.02% from lipoic acid products, 14.86% from carnosine products, 11.88% from etoricoxib, 5.95% from phosphatidylcholine products, and 1.29% from other supplementary products [2] - As of September 30, the number of shareholders increased to 11,100, with an average of 8,049 circulating shares per person, marking a 160.64% increase [2] Group 3: Financial Performance - For the first half of 2025, Fujilai reported revenue of 224 million yuan, a year-on-year growth of 3.36%, and a net profit attributable to shareholders of 43.08 million yuan, reflecting a significant year-on-year increase of 12,430.96% [2] - Since its A-share listing, Fujilai has distributed a total of 153 million yuan in dividends, with 116 million yuan distributed over the past three years [3]

Group 1 - Fujilai's stock price increased by 0.24% on September 25, with a trading volume of 43.61 million yuan. The margin trading data shows a financing purchase amount of 3.72 million yuan and a net financing purchase of 159,200 yuan for the day [1] - As of September 25, the total margin trading balance for Fujilai is 74.99 million yuan, accounting for 6.10% of its market capitalization, indicating a high level compared to the past year [1] - Fujilai's main business includes the research, production, and sales of active pharmaceutical ingredients and health product raw materials, with revenue contributions from various product lines: 66.02% from alpha-lipoic acid series, 14.86% from carnosine series, 11.88% from etoricoxib, and 5.95% from phosphatidylcholine series [1] Group 2 - As of September 19, Fujilai has 11,000 shareholders, a decrease of 4.22% from the previous period, while the average circulating shares per person increased by 4.40% to 3,088 shares [2] - For the first half of 2025, Fujilai reported a revenue of 224 million yuan, a year-on-year increase of 3.36%, and a net profit attributable to shareholders of 43.08 million yuan, a significant year-on-year increase of 12,430.96% [2] - Fujilai has distributed a total of 153 million yuan in dividends since its A-share listing, with 116 million yuan distributed over the past three years [3]

Core Insights - Fujilai (SZ301258) reported a significant decline in financial performance for the year 2024, with total revenue of 429.47 million yuan, a decrease of 12.23% compared to 2023 [1][2] - The net profit attributable to shareholders dropped to 16.41 million yuan, reflecting an 85.38% decline year-on-year [1][2] - The company experienced a substantial loss in net profit after deducting non-recurring items, amounting to -8.92 million yuan, a decrease of 109.96% [1][2] Financial Performance - Total revenue for 2024 was 429,468,011.82 yuan, down from 489,292,586.96 yuan in 2023, marking a 12.23% decline [2][3] - Net profit attributable to shareholders was 16,406,148.23 yuan, compared to 112,181,787.31 yuan in 2023, a decrease of 85.38% [2][3] - The net profit after deducting non-recurring items was -8,924,873.45 yuan, down from 89,606,898.67 yuan in 2023, indicating a decline of 109.96% [2][3] - Operating cash flow net amount was 47,068,013.45 yuan, a decrease of 50.33% from 94,768,588.39 yuan in 2023 [2][3] Revenue Breakdown - Revenue from external sales was 211.23 million yuan, a decline of 31.39%, while domestic sales revenue increased by 20.31% to 218.24 million yuan [2][3] - Sulfuric acid series revenue was 276.48 million yuan, down 26.25% year-on-year [2][3] - The revenue from the raw material drug, Arixib, surged by 835.06% to 62.98 million yuan [2][3] Product and Business Segmentation - The pharmaceutical main business accounted for 99.19% of total revenue, with a total of 426,006,805.49 yuan, down 11.82% from the previous year [3] - The sulfuric acid series products contributed 64.38% of total revenue, while the phosphatidylcholine series and the dipeptide series accounted for 9.57% and 10.58%, respectively [3] - Other business segments saw a significant decline of 44.10%, contributing only 3.46 million yuan to total revenue [3] Company Leadership - The chairman of Fujilai is Qian Xiangyun, who has been in the role since August 2008 and has a background in various positions within the company and local government [4] - Qian Xiangyun's compensation has varied over the years, with a reported salary of 82.40 million yuan in 2024 [5][6]